IDH2 and acute myeloid leukemia: The prognostic significance of mutated IDH in patients with AML is still debated and its impact appears to be contingent on clinical context, co-occurring mutational profile (e.g., NPM1, FLT3-ITD, DNMT3A, complex karyotype, etc.)and hot spot location [4,5,6].